MA26874A1 - Arylpyrazines substituées - Google Patents

Arylpyrazines substituées

Info

Publication number
MA26874A1
MA26874A1 MA26774A MA26774A MA26874A1 MA 26874 A1 MA26874 A1 MA 26874A1 MA 26774 A MA26774 A MA 26774A MA 26774 A MA26774 A MA 26774A MA 26874 A1 MA26874 A1 MA 26874A1
Authority
MA
Morocco
Prior art keywords
arylpyrazines
conditions
diseases
crf1 receptors
substituted
Prior art date
Application number
MA26774A
Other languages
English (en)
Inventor
Taeyoung Yoon
Raymond F Horvath
Kevin J Hodgetts
Dario Doller
Ping Ge
Lombaert Stephane De
Cunyu Zhang
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of MA26874A1 publication Critical patent/MA26874A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)

Abstract

DEPOSANT Société dite : NEUROGEN CORPORATION REVENDICATION DE PRIORITES US 16 Février 2000 60/182,934 US 22 Mai 2000 60/206,455 Voir en annexe le titre de l'invention et le texte de l'abrégé "Arylpyrazines substituées" Il est proposé des arylpyrazines, comprenant des arylpyrazines qui peuvent se lier avec une forte affinité et une grande sélectivité aux récepteurs CRF1, y compris aux récepteurs CRF1 humains. Ainsi, la présente invention comprend des méthodes pour le traitement d'affections et de maladies associées aux récepteurs CRF1, comprenant des affections et maladies en rapport avec le système nerveux central, en particulier des affections et maladies affectives, et des affections et maladies neurologiques aigues et chroniques.
MA26774A 2000-02-16 2002-08-13 Arylpyrazines substituées MA26874A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18293400P 2000-02-16 2000-02-16
US20645500P 2000-05-22 2000-05-22

Publications (1)

Publication Number Publication Date
MA26874A1 true MA26874A1 (fr) 2004-12-20

Family

ID=26878562

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26774A MA26874A1 (fr) 2000-02-16 2002-08-13 Arylpyrazines substituées

Country Status (34)

Country Link
US (3) US6995161B2 (fr)
EP (1) EP1255740B1 (fr)
JP (1) JP2004500383A (fr)
KR (2) KR20030031886A (fr)
CN (1) CN1231473C (fr)
AP (1) AP2002002620A0 (fr)
AT (1) ATE307121T1 (fr)
AU (1) AU783915B2 (fr)
BG (2) BG106968A (fr)
BR (1) BR0108363A (fr)
CA (2) CA2398937A1 (fr)
CR (1) CR6735A (fr)
CZ (1) CZ20022739A3 (fr)
DE (1) DE60114153T2 (fr)
DK (1) DK1255740T3 (fr)
DZ (1) DZ3293A1 (fr)
EA (1) EA006938B1 (fr)
EE (1) EE200200453A (fr)
ES (1) ES2247070T3 (fr)
HK (1) HK1051191A1 (fr)
HR (1) HRP20020747A2 (fr)
HU (1) HUP0301573A3 (fr)
IL (1) IL151020A0 (fr)
IS (1) IS2192B (fr)
MA (1) MA26874A1 (fr)
MX (1) MXPA02007868A (fr)
NO (1) NO324473B1 (fr)
NZ (1) NZ520484A (fr)
OA (1) OA12178A (fr)
PL (1) PL365238A1 (fr)
SK (1) SK11542002A3 (fr)
TW (1) TWI232215B (fr)
WO (1) WO2001060806A2 (fr)
YU (1) YU61002A (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1330452T3 (da) 2000-09-20 2009-03-16 Ortho Mcneil Janssen Pharm Pyrazinderivater som modulatorer af tyrosinkinaser
MXPA03010692A (es) * 2001-05-22 2004-07-01 Neurogen Corp 5-sustituidas-2-arilpiridina como moduladores del factor 1 de liberacion de corticotropina.
EP1399428A1 (fr) * 2001-06-12 2004-03-24 Neurogen Corporation 2,5-diarylpyrazines, 2,5-diarylpyridines et 2,5-diarylpyrimidines utilises comme modulateurs de recepteurs crf1
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
AU2002343557A1 (en) * 2001-11-21 2003-06-10 Pharmacia And Upjohn Company Substituted aryl 1,4-pyrazine derivatives
US6964965B2 (en) 2002-04-26 2005-11-15 Pharmacia & Upjohn Substituted pyrazine derivatives
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
CA2496197A1 (fr) * 2002-08-20 2004-03-04 Neurogen Corporation 2-arylpyrazines substituees en 5 comme modulateurs sur les recepteurs crf
EP1539736A1 (fr) * 2002-09-12 2005-06-15 Pharmacia & Upjohn Company LLC Derives 1,4-pyrazine substitues
CA2499133A1 (fr) * 2002-11-21 2004-06-03 Pharmacia & Upjohn Company Llc Composes de pyrazine en tant que modulateurs de crf
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
DK2476667T3 (da) 2003-02-26 2014-09-15 Sugen Inc Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer
CA2524519A1 (fr) * 2003-05-09 2004-11-18 Pharmacia & Upjohn Company Llc Composes utilises comme antagonistes du recepteur de type 1 de la corticoliberine (crf)
MXPA05012081A (es) 2003-05-09 2006-02-22 Pharmacia & Upjohn Co Llc Derivados de pirimidina sustituidos.
CN1812981A (zh) * 2003-06-27 2006-08-02 万有制药株式会社 杂芳氧基含氮饱和杂环衍生物
CA2543644A1 (fr) * 2003-10-27 2005-05-06 Astellas Pharma Inc. Derives de pyrazine et utilisation pharmaceutique de ce derive
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
US20070078135A1 (en) * 2005-04-18 2007-04-05 Neurogen Corporation Substituted heteroaryl CB1 antagonists
SI1963302T1 (sl) * 2005-12-05 2013-04-30 Pfizer Products Inc. Polimorfne oblike inhibitorja c-met/hgfr
ATE488237T1 (de) * 2005-12-05 2010-12-15 Pfizer Prod Inc Verfahren zur behandlung von abnormalem zellwachstum
SG157264A1 (en) * 2008-06-02 2009-12-29 Inzign Pte Ltd A golf tee and method of producing a golf tee
US7932256B2 (en) * 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
ES2702205T3 (es) 2014-02-14 2019-02-27 Takeda Pharmaceuticals Co Moduladores pirazínicos de GPR6
WO2016105118A2 (fr) 2014-12-24 2016-06-30 주식회사 엘지생명과학 Dérivé de biaryle utilisable en tant qu'agoniste du gpr120
EP4302834A2 (fr) 2016-07-12 2024-01-10 Revolution Medicines, Inc. 3-méthylpyrazines 2,5-disubstituées et 3-méthyl pyrazines 2,5,6-trisubstitués en tant qu'inhibiteurs allostériques de shp2
BR112019014527A2 (pt) 2017-01-23 2020-02-27 Revolution Medicines, Inc. Compostos de piridina como inibidores de shp2 alostéricos
WO2018136265A1 (fr) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Composés bicycliques utilisés en tant qu'inhibiteurs allostériques de shp2
RU2672470C1 (ru) * 2017-07-10 2018-11-15 Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук Способ получения 2,3,5,6-тетрафенил(бензил)пиразина
KR20200070295A (ko) 2017-10-12 2020-06-17 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘, 피라진 및 트리아진 화합물
EP3724189B1 (fr) 2017-12-15 2023-10-04 Revolution Medicines, Inc. Composés polycycliques comme inhibiteurs allosteriques de la shp2
AU2019256719A1 (en) * 2018-04-20 2020-11-05 Virginia Tech Intellectual Properties, Inc. Oxadiazolopyrazines and oxadiazolopyridines useful as mitochondrial uncouplers
US20220340546A1 (en) * 2019-06-14 2022-10-27 Disarm Therapeutics, Inc. Inhibitors of sarm1
GB202006076D0 (en) * 2020-04-24 2020-06-10 Univ Greenwich Interleukin inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2425355A1 (de) 1974-05-25 1975-12-04 Basf Ag Verfahren zur herstellung von pyrazinen
SE421695B (sv) * 1975-04-21 1982-01-25 Merck & Co Inc Sett att framstella piperazinylpyraziner
FR2398738A1 (fr) * 1977-06-22 1979-02-23 Lilly Co Eli Preparation de benzoylurees
US4293552A (en) * 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
US4211870A (en) * 1979-04-06 1980-07-08 Eli Lilly And Company Preparation of substituted 2-aminopyrazines
JPS59144772A (ja) * 1983-02-08 1984-08-18 Ube Ind Ltd 液晶性ピラジン誘導体およびその製法
JPS625970A (ja) * 1985-03-15 1987-01-12 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤
JPH0739398B2 (ja) * 1986-10-04 1995-05-01 宇部興産株式会社 液晶性ピラジン誘導体
NZ227684A (en) * 1988-01-30 1991-07-26 Merck Sharp & Dohme Pyrazine, pyridazine, and pyrimidine derivatives and pharmaceutical compositions
JPH0348666A (ja) 1989-07-17 1991-03-01 Rasa Kogyo Kk 芳香族ジアミン化合物の製造方法
DE3940477A1 (de) * 1989-12-07 1991-06-13 Bayer Ag Hetaryl-substituierte pyridinylpyrimidin-derivate
GB2272216A (en) * 1992-11-04 1994-05-11 Merck Patent Gmbh Liquid crystalline di-, tri- and tetra-fluorinated phenylpyrazines
JP3398152B2 (ja) * 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
AU7095496A (en) * 1995-09-26 1997-04-17 Nippon Soda Co., Ltd. Pyrazole compounds, process for preparing the same, and agrohorticultural bactericide
US6159980A (en) * 1996-09-16 2000-12-12 Dupont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
MA26473A1 (fr) * 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.
BE1011077A3 (fr) 1997-03-28 1999-04-06 Univ Catholique Louvain Composition pharmaceutique, cosmetique et/ou alimentaire aux proprietes anti-oxydantes.
TR200002225T2 (tr) 1998-01-28 2000-12-21 Shionogi & Co., Ltd Yeni trisiklik bileşimler
GB9818881D0 (en) * 1998-08-28 1998-10-21 Glaxo Group Ltd Compounds
WO2000045800A2 (fr) 1999-02-02 2000-08-10 K.U. Leuven Research & Development Effets immunosuppresseurs des derives de pteridine

Also Published As

Publication number Publication date
CN1400970A (zh) 2003-03-05
BG110174A (en) 2009-05-29
EA200200766A1 (ru) 2003-10-30
IL151020A0 (en) 2003-02-12
CA2398937A1 (fr) 2001-08-23
CR6735A (es) 2003-11-25
DE60114153D1 (de) 2006-03-02
HUP0301573A3 (en) 2004-03-29
US20030018035A1 (en) 2003-01-23
KR20080021603A (ko) 2008-03-07
EP1255740B1 (fr) 2005-10-19
CZ20022739A3 (cs) 2003-02-12
US7202250B2 (en) 2007-04-10
NO20023869D0 (no) 2002-08-15
US6995161B2 (en) 2006-02-07
HUP0301573A2 (hu) 2003-12-29
IS2192B (is) 2007-01-15
EA006938B1 (ru) 2006-06-30
BR0108363A (pt) 2004-02-10
IS6488A (is) 2002-07-29
DE60114153T2 (de) 2006-07-06
EP1255740A2 (fr) 2002-11-13
HK1051191A1 (en) 2003-07-25
US20050215559A1 (en) 2005-09-29
DK1255740T3 (da) 2006-02-06
NO324473B1 (no) 2007-10-29
EE200200453A (et) 2003-12-15
MXPA02007868A (es) 2003-02-10
WO2001060806A2 (fr) 2001-08-23
NO20023869L (no) 2002-09-11
NZ520484A (en) 2005-03-24
TWI232215B (en) 2005-05-11
JP2004500383A (ja) 2004-01-08
PL365238A1 (en) 2004-12-27
KR20030031886A (ko) 2003-04-23
ES2247070T3 (es) 2006-03-01
OA12178A (en) 2003-12-24
YU61002A (sh) 2005-06-10
CN1231473C (zh) 2005-12-14
SK11542002A3 (sk) 2003-03-04
BG106968A (bg) 2003-04-30
US20070225287A1 (en) 2007-09-27
AU3849401A (en) 2001-08-27
CA2651825A1 (fr) 2001-08-23
DZ3293A1 (fr) 2001-08-23
AP2002002620A0 (en) 2002-09-30
HRP20020747A2 (en) 2004-12-31
AU783915B2 (en) 2005-12-22
WO2001060806A3 (fr) 2002-02-07
ATE307121T1 (de) 2005-11-15

Similar Documents

Publication Publication Date Title
MA26874A1 (fr) Arylpyrazines substituées
EP1199069A3 (fr) Utilisation d'un agoniste/antagonist estrogènique pour évaluer, améliorer ou maintenir la santé urogénitale
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
HK1074573A1 (en) Tetrahydroquinoline analogues as muscarinic agonists
MA27998A1 (fr) Nouvelle formulation
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
TNSN07258A1 (fr) Derives de quinoleine heteroaromatiques et leur utilisation comme inhibiteurs de pde10
NO20013444D0 (no) Triazolforbindelser med dopamin-D3-reseptor-affinet
ATE259230T1 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
EE200300559A (et) Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks
MA27060A1 (fr) Therapeutique mixte pour le traitement du cancer
WO2001085158A3 (fr) Anandamide et lipides structurellement associes utilises en tant que modulateurs des recepteurs de la vanilloide
AU4038000A (en) 4-substituted quinoline derivatives as gaba receptor ligands
EE05357B1 (et) Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine
GB0320320D0 (en) Novel compounds
YU89103A (sh) Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
IT1293804B1 (it) Diarilalchilpiperazine attive sulle basse vie urinarie
TW200637545A (en) Novel uses for estrogen beta agonists
IL181713A0 (en) Use of il-17f for the treatment and/or prevention of neurological diseases
EP1143942A3 (fr) Nouvelle utilisation de ligands vers des recepteurs gaba b?
WO2001085766A3 (fr) Sequences
DE60320422D1 (de) Verfahren und formulierungen, die sich für die reduktion des cholesteringehalts von eigelb eignen
WO2003027321A3 (fr) Methodes de diagnostic et de traitement de maladies associees a une expression alteree de neurogranine